Revolution Medicines (RVMD) Preferred Stock Liabilities (2019)
Revolution Medicines' (RVMD) quarterly Preferred Stock Liabilities came in at $305.1 million in Q4 2019, little changed quarter-over-quarter from $305.1 million in Q3 2019.
Revolution Medicines (RVMD) Preferred Stock Liabilities (2019) Analysis & Trends
Revolution Medicines' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $305.1 million for Q4 2019.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $305.1 million in Q4 2019; TTM through Dec 2019 was $305.1 million, a N/A change from a year earlier, with the FY2019 full-year figure at $305.1 million, up 48.77% from the prior year.
- Preferred Stock Liabilities steadied at $305.1 million in Q4 2019 per RVMD's latest filing, from $305.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $305.1 million in Q3 2019 and bottomed at $205.1 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 305.11 Mn |
| Sep 30, 2019 | 305.11 Mn |
| Jun 30, 2019 | 295.02 Mn |
| Mar 31, 2019 | 205.08 Mn |